Source comparison
PT-141 Peptide Research: Dosing Comparison
0.75 60–90 min 2–3 hours 12% Preliminary dose-response studies, minimal effective dose determination Subtherapeutic in most models; useful for establishing threshold effects 1.25 50–70 min 2–4 hours 22% Standard dose for rodent translational work (scaled) Bala
This comparison does not assign a generated winner or score.
- 0.75
- 60–90 min
- 2–3 hours
- 12%
- Preliminary dose-response studies, minimal effective dose determination
- Subtherapeutic in most models; useful for establishing threshold effects
- 1.25
- 50–70 min
- 2–4 hours
- 22%
- Standard dose for rodent translational work (scaled)
- Balanced efficacy and tolerability; typical research starting point
- 1.75
- 45–60 min
- 28%
- FDA-approved human dose; primary endpoint in Phase 3 trials
- Highest efficacy without excessive adverse events; gold standard for replication studies
- 2.0+
- 2–5 hours
- 40%+
- Not recommended; used only in dose-limiting toxicity studies
- Adverse event rate exceeds acceptable thresholds for longitudinal research